The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

Athina Giannoudis,Lihui Wang,Andrea Jorgensen,George Xinarianos,Andrea Davies,Sudeep Pushpakom,Triantafilos Liloglou,Jieying-Eunice Zhang,Gemma Austin,Tessa L. Holyoake,Letizia Foroni,Panagiotis D. Kottaridis,Martin C. Müller,Munir Pirmohamed,Richard E. Clark

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

2013

Athina Giannoudis
Lihui Wang
Andrea Jorgensen
George Xinarianos
Andrea Davies
Sudeep Pushpakom
Triantafilos Liloglou
Jieying-Eunice Zhang
Gemma Austin
Tessa L. Holyoake
Letizia Foroni
Panagiotis D. Kottaridis
Martin C. Müller
Munir Pirmohamed
Richard E. Clark

Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is good, many fail to develop an optimal response or lose one. This heterogeneity could be attributed to the presence of human organic cation transporter-1 ( hOCT1 ) single nucleotide polymorphisms (SNPs). In the

Keywords:

Myeloid leukemia
Cancer research
Imatinib
Single-nucleotide polymorphism
Immunology
Medicine
Transfection
Pyrosequencing
Primer (molecular biology)
SNP
imatinib mesylate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations